Ernexa Therapeutics Inc. (ERNA) — Financial statements
Income statement, balance sheet, and cash flow for Ernexa Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 0.58↑755.9% | 0.07 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.10↓59.3% | 0.24 | 0.00 | 0.00 | |
| Gross Profit | 0.00↓100.0% | 0.49↑389.3% | -0.17 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 4↓9.7% | 5↓22.2% | 6↓43.0% | 10↓18.2% | 13 | |
| General & Administrative Expenses | 5↓60.7% | 13↓10.0% | 15↓11.9% | 17↑12.4% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 5↓60.7% | 13↓10.0% | 15↓11.9% | 17↑12.4% | 15 | |
| Other Expenses | 0.00↑100.0% | -2↓441.9% | 0.46↓92.6% | 6↓92.7% | 86 | |
| Operating Expenses | 9↓42.3% | 16↓22.9% | 21↓36.9% | 33↓70.8% | 114 | |
| Total Costs & Expenses | 9↓42.7% | 16↓23.3% | 21↓36.2% | 33↓70.8% | 114 | |
| Operating Results | ||||||
| Operating Income | -9↑40.5% | -16↑25.8% | -21↑36.4% | -33↑70.8% | -114 | |
| Depreciation & Amortization | 0.26↓83.9% | 2↑45.9% | 1↑126.0% | 0.50↑8.3% | 0.46 | |
| EBITDA | -14↑61.7% | -36↓81.2% | -20↑17.0% | -24↑80.3% | -122 | |
| EBIT | -14↑62.7% | -38↓79.3% | -21↑14.1% | -25↑80.0% | -122 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.06↑100.9% | -7↓1266.2% | -0.48↓1486.7% | -0.03↑59.5% | -0.07 | |
| Interest Income | 0.08↓66.7% | 0.25↑80.4% | 0.14 | 0.00 | 0.00 | |
| Interest Expense | 0.03↓99.6% | 7↑999.7% | 0.61↑1946.7% | 0.03↓59.5% | 0.07 | |
| Non-Operating Income | 5↓78.3% | 22↑28411.5% | -0.08↑99.1% | -9↓200.4% | 9 | |
| Other Income / Expenses | -5↑83.3% | -29↓5279.7% | -0.54↓106.2% | 9↑199.2% | -9 | |
| Income Before Tax | -14↑68.3% | -45↓105.4% | -22↑11.7% | -25↑80.0% | -122 | |
| Income Tax Expense | -0.05↓250.0% | 0.03↑1100.0% | -0.00↓106.7% | 0.05↓29.7% | 0.06 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -14↑68.4% | -45↓105.6% | -22↑11.8% | -25↑79.9% | -123 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -14↑68.4% | -45↓105.6% | -22↑11.8% | -25↑79.9% | -123 | |
| Bottom-Line Net Income | -14↑68.4% | -45↓105.5% | -22↑11.8% | -25↑79.9% | -123 | |
| EPS (Basic) | -56.00↓42.7% | -39.25↑61.5% | -102.00↑49.4% | -201.50↑85.8% | -1,415.25 | |
| EPS (Diluted) | -56.00↓42.7% | -39.25↑61.5% | -102.00↑49.4% | -201.50↑85.8% | -1,415.25 | |
| Weighted Average Shares | 0.25↓77.8% | 1↑434.4% | 0.21↑74.2% | 0.12↑40.9% | 0.09 | |
| Weighted Average Diluted Shares | 0.25↓77.8% | 1↑434.4% | 0.21↑74.2% | 0.12↑40.9% | 0.09 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.